This article is available online at http://www.jlr.org hydrolase encoded by the ASAH1 gene. The main clinical features include painful and progressively deformed joints, subcutaneous nodules, a hoarse cry due to laryngeal involvement, and premature death. Hepatosplenomegaly and nervous system dysfunction may also occur ( 1, 2 ). Although the pathogenesis of FD is still unclear in terms of the molecular lesions caused by ceramide storage, the involvement of aCDase defi ciency is unquestionable. Recent interest in aCDase also stems from the fact that this enzyme appears to modulate cell functions by controlling the levels of ceramide and sphingoid bases, which are both considered as putative bioactive molecules ( 3 ).Diagnosis of FD must be biochemically confi rmed by the demonstration of defi cient activity of aCDase, which can then be further documented by characterization of the ASAH1 molecular defects. Although aCDase is a very well known enzyme, existing methods for determining its activity and for FD diagnosis still exhibit many disadvantages. The methods that have been used for FD diagnostic purposes can be classifi ed into three groups: i ) aCDase enzymatic assays ( 4-16 ), classically performed with radiolabeled substrates ( 4-13 ), which are rather water-insoluble and require at least one detergent (see Table 1 ) ; ii ) loading tests, consisting of the addition of exogenous radiolabeled sphingolipids, e.g., ceramide ( 17, 18 ), sulfatide ( 19,20 ), or sphingomyelin ( 21 ), on cultured living cells and the study of their metabolism; and iii ) determination of accumulated ceramide, either by sophisticated chromatographic methods ( 22,23 ) or through the use of the diacylglycerol kinase assay in the presence of ␥ [ Farber disease (FD) is a rare inherited lipid storage disorder, also known as lipogranulomatosis, which is characterized by accumulation of ceramide in the cells and tissues of patients ( 1, 2 ). This accumulation is the consequence of a defi cient intracellular activity of aCDase, a lysosomal